Pfizer to Report Third-Quarter Results Tuesday
Analysts expect Pfizer's third-quarter earnings per share to fall 16% to 73 cents, with revenue estimated at $15.88 billion.
Updated on Nov. 2, 2026 in Healthcare
Pfizer is scheduled to release its third-quarter report before U.S. markets open on Tuesday, November 3, 2026. Analysts estimate earnings per share at 73 cents, down 16%, and revenue of $15.88 billion, down 4.6%.
Why it matters
The report will show how Pfizer is managing a period of declining revenue and approaching patent expirations. Investors will be watching for updates on the company's cost-cutting program and its anti-obesity candidate tied to Metsera.
Analysts estimate Pfizer's third-quarter earnings per share at 73 cents, down 16%, and revenue at $15.88 billion, down 4.6%. These figures are pre-report forecasts and have not yet been confirmed by company filings.
The players
Pfizer
Pfizer is a major U.S. pharmaceutical company known for drugs including Eliquis and Ibrance.
The details
Eliquis, Ibrance, and Xtandi are approaching loss of exclusivity, which is expected to pressure revenue in coming years. Management has projected high single-digit growth from 2028 to 2033, while analysts expect no growth over the next 10 years.
Timeline
Tuesday, November 3, 2026: Pfizer releases its third-quarter report before U.S. markets open.
2028 to 2033: Pfizer management projects high single-digit growth.
Market Landscape
Pfizer faces the loss of exclusivity for several major drugs, including Eliquis, Ibrance, and Xtandi, a pattern that pressures large pharmaceutical companies to replace lost revenue with new products. The company's anti-obesity candidate tied to Metsera reflects how drugmakers are pursuing growth areas to offset expiring patents.
Patients relying on Eliquis, Ibrance, or Xtandi may see future changes in generic availability as these drugs approach loss of exclusivity. Investors and retirement account holders with pharmaceutical holdings should watch the earnings report for signals on Pfizer's growth outlook.
The takeaway
Large drugmakers depend on a steady pipeline of new products to offset expiring patents. Pfizer's report will show whether its cost cuts and new candidates can support growth through the coming decade.
What happens next
Pfizer releases its third-quarter report before U.S. markets open on Tuesday, November 3, 2026.
Further reading
Track the latest developments in the Healthcare sector for more context on pharmaceutical earnings and patent pressures.
